An experience of using a ribosomal-proteoglycan complex preparation in recurrent bronchitis in infants and toddlers
The efficacy of using a ribosomal-proteoglycan complex preparation (Ribomunil) in recurrent bronchitis (RB) in infants and toddlers was assessed. The examination included 43 children with RB aged from 1.5 to 6 years. The patients of the reference group (n = 23) received standard therapy, the basic group (n = 20) received a 6-month course of Ribomunil. Assessment of the efficacy of therapy was performed by the number of episodes of acute respiratory infections (ARI) and results of viral and bacteriological tests of smears from the upper respiratory tract. In the basic group, the number of ARI decreased from 4.4 ± 0.3 to 3.2 ± 0.3, of their complicated forms: from 17.4 to 0% (p < 0.05); besides, the percentage of children, referred to the frequently ill category, reduced from 75 to 30% (p < 0.01). The percentage of children with carriage of pathogenic flora decreased from 55 to 15% (p < 0.01). In the reference group, no such changes were observed. The use of a six-month therapeutic course of the ribosomal-proteoglycan complex preparation considerably decreases the frequency and severity of ARI episodes and contributes to a decrease of the level of carrying pathogenic microflora.